Evidence map›Paper›PMID 40385498›Full record

ArticleJournal of diabetes and metabolic disorders2025

Effects of multi-strain synbiotic supplementation on liver enzymes, insulin resistance, anthropometric, and inflammatory indices in overweight and obese adults with fatty liver and diabetes: a randomized controlled trial.

Aryan M Yazdani, Mohammad Reza Fattahi, Mohammad Hassan Eftekhari, Afsane Ahmadi, Mahmood Soveid, Morteza Zare, Mohammad Ali Mohsenpour

Abstract read
In one paragraph

Article in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aryan M YazdaniGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Reza FattahiGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Hassan EftekhariResearch Center for Health Sciences, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Afsane AhmadiNutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Mahmood SoveidEndocrinology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Morteza ZareNutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Ali MohsenpourStudent Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Synbiotic supplements have been shown to affect type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD), however; results remain inconclusive. Thus, the present study was designed to investigate the potential effect of multi-strain synbiotic supplements on liver enzymes, insulin resistance, anthropometric indices, and inflammatory markers in overweight/obese patients with NAFLD and T2DM. Method: In a 12-week triple-blinded randomized controlled trial, 40 eligible overweight or obese adults with NAFLD and T2DM were randomly assigned to two groups to consume either synbiotic supplements or a placebo along a low-calorie diet. Participants were assessed for liver enzymes, anthropometric and glycemic indices, and lipid profiles before and after the study. Result: After the study period, using intention-to-treat approach 20 individuals were included in the final analysis for each group. The intervention group showed significant reductions in within group analysis for insulin levels, weight, and BMI ( Conclusion: In the present study, synbiotic supplements showed improvements in insulin levels, weight, BMI, and AST. However, in comparison to the control group no beneficial effects were observed. Further studies are recommended to draw more definitive conclusions.

Indexed as

DiabetesFatty liverPrebioticProbioticSynbiotic

Identifiers

PMID40385498
PMCPMC12081805

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.